ANI Pharmaceuticals, a Baudette, Minnesota-headquartered specialty pharmaceutical company, has acquired WellSpring Pharma Services, an Oakville, Canada-headquartered contract development and manufacturing organization (CDMO) of drug products, for $18 million in cash. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. ANI Pharmaceuticals Canada Inc is located in Oakville, ON, Canada and is part of the Pharmaceutical Manufacturing Industry.

The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

United StatesANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Landec Nominates Three New Members to its Board of Directors, Providing Deep Expertise to Both Business SegmentsANI Pharmaceuticals Reports Second Quarter 2020 ResultsANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board ofANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive OfficerANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter 2020 Financial ResultsSensorion appoints five renowned experts to its Scientific Advisory BoardANI Pharmaceuticals Announces Acquisition of Fluconazole TabletsANI Pharmaceuticals Announces Launch of Mexiletine Hydrochloride CapsulesAligos Therapeutics Appoints Lesley Ann Calhoun as Chief Financial Officer

Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

ANI Pharmaceuticals Reports Second Quarter 2020 Results 08/06/2020. There are 6 companies in the ANI Pharmaceuticals Canada Inc corporate family. How ANI Pharmaceuticals Plans to Take Down a Price-Gouging Giant A small-cap pharmaceuticals company may hold the solution to a nearly 100,000% drug price hike. READ MORE > ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors 08/06/2020.

Baudette, MN 56623 You can sign up for additional alert options at any time.At ANI Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party.

Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; competition from other products; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission ("SEC"), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. The Company develops, manufactures, and markets branded and generic prescription pharmaceuticals. ANI Pharmaceuticals manufactures oral solid dose products, as well as liquid and topical products in the State of Minnesota.210 Main Street West ANI Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 44 drugs in the United States.

Patrick Walsh , ANI's Interim President and CEO, stated, "This is our sixth generic product launch in 2020. If you experience any issues with this process, please contact us for further assistance.

For more information, please visit our website To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Non-US country and region specific information is not available on this page.

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP ) today announced the launch of Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg. The current annual U.S. market for this product is approximately $40 million , according to IQVIA/IMS Health.